Research programme: anti-infectives - Wockhardt

Drug Profile

Research programme: anti-infectives - Wockhardt

Alternative Names: Ketolides - Wockhardt; Oxas - Wockhardt; WCK 2370; WCK 2664; WCK 2832; WCK 2924; WCK 3023; WCK 919; WCK-1734; WCK-4086; WCK-4897; WCK-4918

Latest Information Update: 16 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Wockhardt
  • Class Ketolides; Oxazolidinones
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections; Gram-negative infections; Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
  • Research Nosocomial infections; Urinary tract infections

Most Recent Events

  • 19 Jun 2016 Antimicrobial data from a preclinical studies in Streptococcus pneumoniae infection were presented at 56th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2016)
  • 08 Dec 2015 Preclinical trials in Gram-negative infections, Nosocomial infections and Urinary tract infections in India (unspecified route)
  • 22 Apr 2015 Preclinical development is underway in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top